All Oncology News

Tony Philip, MD, discusses advances made in the treatment of patients with colorectal cancer.

John L. Marshall, MD, has made it his mission to improve the lives of patients with GI cancers through innovative research, personalized medicine, and focused advocacy.

Aditya Bardia, MD, MPH, discusses the integration of ADCs and immunotherapy into the treatment landscape in metastatic TNBC and the future of AKT inhibitors in the field.

Daniel Lin, MD, MS, discusses pivotal trials examining important targeted agents for patients with cholangiocarcinoma and the importance of comprehensive genomic testing to guide treatment decisions.

Lara A. Kujtan, MD, discusses the data that support the current utility of osimertinib in EGFR-mutant NSCLC and where else it is currently being explored.

Seema A. Bhat, MD, discusses updates from key studies and highlighted the promise of novel PI3K inhibitors in chronic lymphocytic leukemia.

When the coronavirus disease 2019 pandemic started upending health care services throughout the United States a year ago, the oncology community moved quickly to develop guidance on selecting therapies and setting treatment schedules for many cancers to allow for less frequent in-patient visits to clinics and infusion centers.

Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

Syed Kazmi, MD, discusses choosing among regorafenib and TAS-102 in the treatment of patients with metastatic colorectal cancer.

R. Gregory Bociek, MD, discusses the role of minimal residual disease in patients with chronic lymphocytic leukemia.

The FDA has granted a fast track designation to poziotinib for use in previously treated patients with HER2 exon 20 mutations.

The FDA has extended the review period for the new drug application for belumosudil for use in patients with chronic graft-versus-host disease to allow for more time to review additional data submitted by the biopharmaceutical company.

The FDA has granted an orphan drug designation to the orally bioavailable, highly-specific G protein-coupled estrogen receptor agonist LNS8801 for the treatment of patients with metastatic uveal melanoma.

Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.

Kaushal Parikh, MD, MBBS, highlights ongoing research exploring systemic approaches in early-stage non¬–small cell lung cancer and shares where future efforts are headed.

Bipolar androgen therapy demonstrated clinically meaningful activity and a good safety profile compared with enzalutamide in asymptomatic men with metastatic castration-resistant prostate cancer who progressed on abiraterone acetate.

The FDA's accelerated approval of sacituzumab govitecan-hziy in April 2020, filled a previously undefined role for antibody-drug conjugates in patients with triple-negative breast cancer.

Atrayee Basu-Mallick, MD, discusses the emerging role of ctDNA as a predictive biomarker in early-stage CRC and the growing importance of molecular testing in the advanced-stage setting.

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

The FDA has approved tivozanib (Fotivda) for the treatment of adult patients with relapsed/refractory advanced renal cell carcinoma following 2 or more prior systemic therapies.

The field of triple-negative breast cancer is pushing to improve treatment by answering questions regarding biomarkers of response, defining the utility of neoadjuvant approaches, and exploring potential combinations with checkpoint inhibitors and PARP inhibitors.

Sattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.

Prognosis and treatment recommendations for patients with breast cancer and brain metastases rely heavily on the tumor subtype; however, evolving evidence demonstrates that receptor expression and subtype grouping may change during the course of the patient’s disease.

Kira Gritsman, MD, PhD, discusses the significance of the VIALE-A trial examining venetoclax plus azacitidine in older patients with AML and the emergence of minimal residual disease as an important end point in clinical trials.

There are a number of strategies to reduce margin positivity, particularly after partial mastectomy, but the relative effectiveness of each varies, as do the data that support their use.

FDA approval of vaccines to prevent coronavirus disease 2019 is giving new focus to technologies with the potential to treat patients with cancer.

Determining the appropriate sequencing for chemotherapy and radiation in patients with locally advanced rectal cancer is important and may depend on whether the goal of therapy is nonoperative management.

Interferon-alpha has been shown to significantly improve both myelofibrosis-free survival and overall survival over hydroxyurea and phlebotomy only in patients with polycythemia vera.